MorphoSys AG (MPSYF)
USD 73.27
(2.1%)
USD 73.27
(2.1%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 2.02 Billion EUR | -15.46% |
| 2022 | 2.39 Billion EUR | -6.23% |
| 2021 | 2.55 Billion EUR | 54.04% |
| 2020 | 1.65 Billion EUR | 234.28% |
| 2019 | 496.43 Million EUR | -7.86% |
| 2018 | 538.76 Million EUR | 29.7% |
| 2017 | 415.39 Million EUR | -10.4% |
| 2016 | 463.6 Million EUR | 15.88% |
| 2015 | 400.07 Million EUR | -6.19% |
| 2014 | 426.47 Million EUR | -4.73% |
| 2013 | 447.65 Million EUR | 99.59% |
| 2012 | 224.28 Million EUR | -1.8% |
| 2011 | 228.41 Million EUR | 7.46% |
| 2010 | 212.55 Million EUR | 3.14% |
| 2009 | 206.09 Million EUR | 1.38% |
| 2008 | 203.29 Million EUR | 10.06% |
| 2007 | 184.71 Million EUR | 44.48% |
| 2006 | 127.84 Million EUR | 59.57% |
| 2005 | 80.11 Million EUR | 43.59% |
| 2004 | 55.79 Million EUR | 21.93% |
| 2003 | 45.75 Million EUR | 7.94% |
| 2002 | 42.39 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 1.83 Billion EUR | -9.61% |
| 2023 FY | 2.02 Billion EUR | -15.46% |
| 2023 Q3 | 2.1 Billion EUR | -1.94% |
| 2023 Q1 | 2.22 Billion EUR | -6.98% |
| 2023 Q4 | 2.02 Billion EUR | -3.55% |
| 2023 Q2 | 2.14 Billion EUR | -3.9% |
| 2022 Q2 | 2.5 Billion EUR | 2.08% |
| 2022 Q1 | 2.45 Billion EUR | -3.87% |
| 2022 Q3 | 2.84 Billion EUR | 13.57% |
| 2022 Q4 | 2.39 Billion EUR | -15.87% |
| 2022 FY | 2.39 Billion EUR | -6.23% |
| 2021 Q4 | 2.55 Billion EUR | -11.36% |
| 2021 FY | 2.55 Billion EUR | 54.04% |
| 2021 Q1 | 1.64 Billion EUR | -0.58% |
| 2021 Q2 | 1.57 Billion EUR | -4.39% |
| 2021 Q3 | 2.88 Billion EUR | 82.83% |
| 2020 Q1 | 1.33 Billion EUR | 168.98% |
| 2020 FY | 1.65 Billion EUR | 234.28% |
| 2020 Q4 | 1.65 Billion EUR | 20.24% |
| 2020 Q3 | 1.38 Billion EUR | -3.09% |
| 2020 Q2 | 1.42 Billion EUR | 6.65% |
| 2019 Q3 | 541.14 Million EUR | -2.81% |
| 2019 FY | 496.43 Million EUR | -7.86% |
| 2019 Q1 | 556.3 Million EUR | 3.26% |
| 2019 Q2 | 556.79 Million EUR | 0.09% |
| 2019 Q4 | 496.43 Million EUR | -8.26% |
| 2018 Q3 | 578.7 Million EUR | 5.65% |
| 2018 Q2 | 547.75 Million EUR | 39.68% |
| 2018 Q1 | 392.15 Million EUR | -5.6% |
| 2018 Q4 | 538.76 Million EUR | -6.9% |
| 2018 FY | 538.76 Million EUR | 29.7% |
| 2017 FY | 415.39 Million EUR | -10.4% |
| 2017 Q4 | 415.39 Million EUR | -1.16% |
| 2017 Q3 | 420.29 Million EUR | -6.82% |
| 2017 Q2 | 451.04 Million EUR | -0.63% |
| 2017 Q1 | 453.89 Million EUR | -2.09% |
| 2016 Q1 | 391.54 Million EUR | -2.13% |
| 2016 Q2 | 380.59 Million EUR | -2.8% |
| 2016 Q4 | 463.6 Million EUR | 23.75% |
| 2016 Q3 | 374.61 Million EUR | -1.57% |
| 2016 FY | 463.6 Million EUR | 15.88% |
| 2015 Q1 | 431.23 Million EUR | 1.12% |
| 2015 Q2 | 429.37 Million EUR | -0.43% |
| 2015 Q3 | 422.46 Million EUR | -1.61% |
| 2015 Q4 | 400.07 Million EUR | -5.3% |
| 2015 FY | 400.07 Million EUR | -6.19% |
| 2014 Q3 | 434.07 Million EUR | -0.03% |
| 2014 FY | 426.47 Million EUR | -4.73% |
| 2014 Q2 | 434.21 Million EUR | -0.62% |
| 2014 Q4 | 426.47 Million EUR | -1.75% |
| 2014 Q1 | 436.92 Million EUR | -2.4% |
| 2013 Q3 | 456.41 Million EUR | 85.24% |
| 2013 Q4 | 447.65 Million EUR | -1.92% |
| 2013 FY | 447.65 Million EUR | 99.59% |
| 2013 Q1 | 232.83 Million EUR | 3.81% |
| 2013 Q2 | 246.38 Million EUR | 5.82% |
| 2012 Q3 | 224.91 Million EUR | 0.47% |
| 2012 Q4 | 224.28 Million EUR | -0.28% |
| 2012 FY | 224.28 Million EUR | -1.8% |
| 2012 Q1 | 227.63 Million EUR | -0.34% |
| 2012 Q2 | 223.86 Million EUR | -1.66% |
| 2011 FY | 228.41 Million EUR | 7.46% |
| 2011 Q3 | 239.66 Million EUR | 0.44% |
| 2011 Q4 | 228.41 Million EUR | -4.7% |
| 2011 Q2 | 238.61 Million EUR | -3.28% |
| 2011 Q1 | 246.69 Million EUR | 16.06% |
| 2010 Q1 | 211.05 Million EUR | 2.41% |
| 2010 FY | 212.55 Million EUR | 3.14% |
| 2010 Q3 | 210.47 Million EUR | -7.1% |
| 2010 Q4 | 212.55 Million EUR | 0.99% |
| 2010 Q2 | 226.54 Million EUR | 7.34% |
| 2009 FY | 206.09 Million EUR | 1.38% |
| 2009 Q4 | 206.09 Million EUR | 0.0% |
| 2008 FY | 203.29 Million EUR | 10.06% |
| 2007 FY | 184.71 Million EUR | 44.48% |
| 2006 FY | 127.84 Million EUR | 59.57% |
| 2005 FY | 80.11 Million EUR | 43.59% |
| 2004 FY | 55.79 Million EUR | 21.93% |
| 2003 FY | 45.75 Million EUR | 7.94% |
| 2002 FY | 42.39 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | 1.87 Million USD | -107804.191% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -405942.657% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -775441.365% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -19099.462% |
| GB Sciences, Inc. | 103.44 Thousand USD | -1958786.345% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -22542.487% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -11332736.762% |
| Skye Bioscience, Inc. | 11.94 Million USD | -16870.197% |
| Zenith Capital Corp. | 7410.00 USD | -27345530.405% |
| Agentix Corp. | 261.39 Thousand USD | -775100.164% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -103378.837% |
| Biomind Labs Inc. | 73.81 Thousand USD | -2744872.45% |
| ContraFect Corporation | 20.67 Million USD | -9698.884% |
| CSL Limited | 38.02 Billion USD | 94.671% |
| CytoDyn Inc. | 11.13 Million USD | -18096.042% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -262837.389% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | -7151.328% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -421558.869% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -2800026.046% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -572924.264% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | -1456.178% |
| SQZ Biotechnologies Company | 107.18 Million USD | -1790.445% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -61062.206% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | -5116.133% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -141399.018% |
| Mesoblast Limited | 667.9 Million USD | -203.385% |
| Marizyme, Inc. | 22.01 Million USD | -9104.199% |
| Genus plc | 1.02 Billion USD | -96.94% |
| Pharming Group N.V. | 462.85 Million USD | -337.786% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -323075.632% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -530102.292% |
| IMV Inc. | 31.33 Million USD | -6366.857% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -48773.624% |
| MultiCell Technologies, Inc. | 126.22 USD | -1605380357.138% |
| ONE Bio Corp. | 70.08 Million USD | -2791.199% |
| RVL Pharmaceuticals plc | 128.51 Million USD | -1476.773% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | -5660.002% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -139757.197% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | -6651.006% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -73682.376% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -294642.178% |
| Alpha Cognition Inc. | 2.45 Million USD | -82533.391% |
| Enzolytics Inc. | 361.7 Million USD | -460.209% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 55.392% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | -4147.854% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -316681.397% |
| Genscript Biotech Corporation | 3.38 Billion USD | 40.163% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -27966.177% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -2653737.668% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -629568.562% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -775183.212% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -218261.678% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -149074.126% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -518979.841% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -215536.366% |
| Helix BioMedix, Inc. | 3.02 Million USD | -66883.59% |
| EV Biologics, Inc. | 431.71 Thousand USD | -469264.258% |
| Q BioMed Inc. | 3.51 Million USD | -57539.067% |
| Capstone Therapeutics Corp. | 52.7 Million USD | -3744.92% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | -354.015% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 14.56 Million USD | -13816.694% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -77739.364% |
| HST Global, Inc. | 1526.00 USD | -132785693.775% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -87719000.13% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -204999.079% |
| Halberd Corporation | 10.13 Thousand USD | -20000997.749% |
| Resverlogix Corp. | 8.11 Million USD | -24869.947% |
| Cell Source, Inc. | 195.17 Thousand USD | -1038123.513% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -8894642.167% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 7.37 Million USD | -27367.373% |
| Ember Therapeutics, Inc. | 184.00 USD | -1101255994.022% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 62.24 Thousand USD | -3255123.0% |
| Kadimastem Ltd | 2.3 Million USD | -87844.482% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -2118209.39% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -3548979.085% |
| LadRx Corporation | 2.3 Million USD | -87699.602% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -572924.264% |
| Affymax, Inc. | 7.44 Million USD | -27124.388% |
| Itoco Inc. | 1.4 Million USD | -144629.072% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -1911514.352% |
| Mobile Lads Corp. | 52.00 USD | -3896752232.692% |
| International Stem Cell Corporation | 5.39 Million USD | -37493.9% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | 137.63 Thousand USD | -1472103.325% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -1417178.357% |
| Qrons Inc. | 420.00 USD | -482454950.714% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -525571.507% |
| SYBLEU INC | 330.46 Thousand USD | -613064.123% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -366905.581% |
| Rebus Holdings, Inc. | 5000.00 USD | -40526124.26% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -494819.964% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -13407.094% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -12122.156% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -2564850.903% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -234243.138% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -26856.382% |
| Neutra Corp. | 2851.00 USD | -71073600.912% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -6152.889% |
| PureTech Health plc | 693.97 Million USD | -191.987% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -25005.797% |
| IXICO plc | 15.84 Million USD | -12689.217% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -24366.448% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -1861.123% |
| CSL Limited | 38.02 Billion USD | 94.671% |
| Cellectis S.A. | 333.99 Million USD | -506.69% |